Skip to content ↓

Topic

DNA

Download RSS feed: News Articles / In the Media / Audio

Displaying 1 - 15 of 65 news clips related to this topic.
Show:

The New York Times

The 2024 Nobel Prize in Physiology or Medicine has been awarded to Victor Ambros '75, PhD '79 and Gary Ruvkun for the discovery of microRNA, “a tiny class of RNA molecules that play a crucial role in determining how organisms mature and function – and how they sometimes malfunction,” reports Teddy Rosenbluth and Derrick Bryson Taylor for The New York Times. Ambros and Ruvkun “had been postdoctoral fellows at the same time at Massachusetts Institute of Technology,” they explain . “As they studied C. elegans, they at first felt a smidgen of friendly competition as they each started their own labs in the Boston area, Dr. Ambros said.”

The Washington Post

Victor Ambros '75, PhD '79 and Gary Ruvkun have won the 2024 Nobel Prize in Physiology or Medicine for the discovery of microRNAs, report Mark Johnson and Lizette Ortega for The Washington Post. “Ambros and Ruvkunhad worked together as postdoctoral researchers in the lab of Nobel laureate and MIT Professor Robert Horvitz. “What the microRNAs really end up revealing for us is a way that parts of our genome can communicate with other parts of the genome,” says Ambros. “The significance of this discovery of microRNAs is that it allowed us to be aware of a very complex and nuanced layer of regulation whereby genes in our cells talk to each other.”

NBC News

Victor Ambros ‘75, PhD ‘79 and Gary Ruvkun have won the 2024 Nobel Prize in Physiology or Medicine for “their groundbreaking work on how genes behave,” reports Patrick Smith for NBC News. Ambros and Ruvkun, who worked as postdocs in the lab of Professor H. Robert Horvitz in the late 1980s, discovered how microRNA molecules play a key role in gene regulation. "The pair sought to explore how nerve cells and muscle cells, for example, have very different characteristics despite having the same genetic information," writes Smith.

The Boston Globe

The Boston Globe’s Angelina Parrillo interviews Jasmina Aganovic ’09 about her beauty company Arcaea, which reconstructs data from extinct flowers to produce fragrances. “I viewed fragrance as this remarkable emotional storytelling category and people don’t view science as being associated with creativity, emotion, or storytelling,” Aganovic says. “I think that that’s very far from the truth.”

Newsweek

MIT researchers have created an amber-like material that preserves DNA so it can store data, improving on current methods that use particles of silica or require freezing, reports Pandora Dewan for Newsweek. The team “demonstrated their material by embedding and subsequently removing a DNA sequence encoding the music for the Jurassic Park theme song,” Dewan explains. “Following this process, they sequenced the molecule and confirmed that no errors had been introduced into the DNA sequence.”

STAT

Writing for STAT, Prof. Kevin Esvelt explores how, “the immense potential benefits of biotechnology are profoundly vulnerable to misuse. A pandemic caused by a virus made from synthetic DNA — or even a lesser instance of synthetic bioterrorism — would not only generate a public health crisis but also trigger crippling restrictions on research.” Esvelt adds: “The world has too much to gain from the life sciences to continue letting just anyone obtain DNA sufficient to cause a pandemic.” 

Wired

Prof. Ron Weiss co-founded Strand Therapeutics, a biotech company developing mRNA therapies, reports Emily Mullin for Wired. “The notion is that genetic circuits can really have significant impact on safety and efficacy,” says Weiss. “This begins to really open up the door for creating therapies whose sophistication can match the underlying complexity of biology.”

Nature

MIT researchers have “used an algorithm to sort through millions of genomes to find new, rare types of CRISPR systems that could eventually be adapted into genome-editing tools,” writes Sara Reardon for Nature. “We are just amazed at the diversity of CRISPR systems,” says Prof. Feng Zhang. “Doing this analysis kind of allows us to kill two birds with one stone: both study biology and also potentially find useful things.”

Forbes

Jasmina Aganovic ’09 founded Future Society, a brand that uses sequenced DNA from extinct flowers to create new scents, reports Celia Shatzman for Forbes. “[With] plants that are from another time, never before have we been able to time travel through smell,” says Aganovic. “But now we can do that, thanks specifically to DNA sequencing. It’s an example of where we're starting off with this concept of limitless nature. It isn't just about stories; it's also about performance.”

Nature

Researchers at MIT and elsewhere have identified key cell types that may protect the brain against Alzheimer’s symptoms, reports Sara Reardon for Nature. “Most Alzheimer’s research has focused on excitatory neurons, which relay electrical signals to activate other neurons,” explains Reardon. “But the authors found that the cells with reelin or somatostatin were inhibitory neurons, which halt neuronal communication. These inhibitory cells might therefore have a previously unknown role in the types of cognitive function that are lost during Alzheimer’s.”

Science

MIT researchers have discovered an RNA-guided DNA-cutting enzyme in eukaryotes, reports Science. “The researchers speculate that eukaryotic cells may have gained the newly identified editing genes from transposable elements—so-called jumping genes—they received from bacteria,” writes Science.

Popular Science

MIT researchers have identified a new biological editing system that could “potentially be even more precise than CRISPR gene editing,” reports Laura Baisas for Popular Science. The new system, based on a protein called Fanzor, is “the first programmable RNA-guided system discovered in eukaryotes,” Baisas notes.

Boston 25 News

Researchers at MIT have developed a new nanoparticle sensor that can detect cancerous proteins through a simple urine test. “The researchers designed the tests to be done on a strip of paper, similar to the at-home COVID tests everyone became familiar with during the pandemic,” writes Lambert. “They hope to make it as affordable and accessible to as many patients as possible.”

The Boston Globe

Boston Globe reporter Ryan Cross spotlights Chroma Medicine, a biotech startup co-founded by MIT researchers that is “developing a new class of gene editing technologies that could control how our genetic code is read without changing the code itself.” Cross explains that Chroma Medicine’s technology could “have broad applications for treating both rare and common diseases.”